In a new commentary for Pharmaceutical Market Europe, Precision for Value’s Austin Speier, VP, Emerging Technology, examines the promise and advantages of integrating digital biomarkers into precision medicine. He highlights the ways life sciences companies are using the innovative technology to measure physiological, cognitive, or behavioral characteristics.

To read the complete commentary, please click here (pgs. 22-23)